PMC6503590_01
Gd-EDTA enhanced T1-weighted sagittal cranial MRI demonstrates multiple
supratentorial contrast-enhanced lesions.
10.1177_1756286419846818-fig1.jpg
PMC6503590_01_10.1177_1756286419846818-fig1.jpg
fig1-1756286419846818
MRI showed multiple gadolinium (Gd)-enhanced T1 lesions supratentorially and infratentorially (Figures 1 and 2) and two enhancing spinal cord lesions at the C5 and D4 level.
Axial FLAIR (a) and Gd-EDTA enhanced T1-weighted sequences (b) on cranial MRI
demonstrate a large lesion in the left cerebellar peduncle.
10.1177_1756286419846818-fig2.jpg
PMC6503590_01_10.1177_1756286419846818-fig2.jpg
fig2-1756286419846818
MRI showed multiple gadolinium (Gd)-enhanced T1 lesions supratentorially and infratentorially (Figures 1 and 2) and two enhancing spinal cord lesions at the C5 and D4 level.
Sagittal Gd-EDTA enhanced T1-weighted sequences on spinal MRI demonstrate
multiple contrast-enhanced lesions at the C2, C7 and D1 level.
10.1177_1756286419846818-fig3.jpg
PMC6503590_01_10.1177_1756286419846818-fig3.jpg
fig3-1756286419846818
MRI revealed multiple new Gd-enhanced T1 lesions in the cervical and thoracic cord (Figure 3).
Clinical evolution after cessation of fingolimod (FTY) in case 1. iv,
intravenous; MP, methylprednisolone; OCR, ocrelizumab; PLEX, plasma
exchange.
10.1177_1756286419846818-fig4.jpg
PMC6503590_01_10.1177_1756286419846818-fig4.jpg
fig4-1756286419846818
The clinical events and measures after FTY cessation are summarized in Figure 4.
PMC6503590_02
Sagittal T2-weighted sequences on cranial MRI demonstrate a large brainstem
lesion extending into the medulla.
10.1177_1756286419846818-fig5.jpg
PMC6503590_02_10.1177_1756286419846818-fig5.jpg
fig5-1756286419846818
MRI revealed a large Gd-enhanced lesion extending from the pons to the medulla (Figure 5).
Clinical evolution after cessation of fingolimod (FTY) in case 2. iv,
intravenous; MP, methylprednisolone; OCR, ocrelizumab.
10.1177_1756286419846818-fig6.jpg
PMC6503590_02_10.1177_1756286419846818-fig6.jpg
fig6-1756286419846818
The clinical events and measures after FTY cessation are summarized in Figure 6.